DSM-5 Diagnosis definition

DSM-5 Diagnosis. A substance abuse diagnosis, as set forth in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, shall be required for program admission. The County may refer or authorize client services, or clients may self-refer.
Sample 1Sample 2Sample 3
DSM-5 Diagnosis means the diagnosis, consistent with the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), resulting from the clinical Assessment of a Member.
Sample 1Sample 2

Examples of DSM-5 Diagnosis in a sentence

  • The Diagnosis should be available at the time of admission, as the existence of a DSM-5 Diagnosis is one of the admission criteria.

  • Has DSM-5 Diagnosis and requires clinical intervention that cannot be provided within a family setting due to the intensity of the treatment and 24/7 supervision requirements, which cannot be replicated in a family setting.

  • Conversely, valid income needs of the CWF must be recognized in the financial planning/budgeting process of the PRF.

  • To give a relaxed constraint, we reverse- engineered NPS logs, then we set service constraints with values greater than twice of the NPS percentile numbers.

  • If soldiers obtain a high GSI (i.e., 2 standard deviations above the mean), then further assessment will verify symptom severity using instruments such as the Beck Depression Inventory (BDI-II; Beck, Steer, & Brown, 1996) or the Beck Anxiety Inventory (BAI; Beck & Steer, 1993).PTSD Checklist for DSM-5 Diagnosis.

  • In Part II, primary time to treatment failure summaries will be repeated for the following subgroups: 1-) Current Primary DSM-5 Diagnosis (schizophrenia and schizophreniform); 2-) Subjects who continued into Part III and those who did not.

  • Primary MCCB composite score summaries will be repeated for the following subgroups: 1-) Current Primary DSM-5 Diagnosis (schizophrenia and schizophreniform); 2-) Subjects who continued into Part III and those who did not.

  • Helpful Notes:Organize your paper using the categories listed above as paper headings: Life-Stage Theory; Risk and Resilience; Systems-Level Impacts, and DSM-5 Diagnosis.

  • DSM-5 Diagnosis Primary - F 32.1 major depressive disorder, single episode, moderate Secondary - as needed Rationale.

  • Classification Quality of the PCL-5 for the DSM-5 Diagnosis of PTSDScore≥Note.

Related to DSM-5 Diagnosis

  • Medical cannabis means the same as that term is defined in Section 26-61a-102.

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Clinical laboratory means a facility for the microbiological, serological, chemical, hematological, radiobioassay, cytological, immunohematological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of a disease or assessment of a medical condition.

  • Disease means an alteration in the state of the body or of some of its organs, interrupting or disturbing the performance of the functions, and causing or threatening pain and weakness or physical or mental disorder and certified by a Medical Practitioner.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Medical evaluation means the process of assessing an individual's health status that includes a medical history and a physical examination of an individual conducted by a licensed medical practitioner operating within the scope of his license.

  • Medication means any drug, chemical, compound, suspension, or preparation in suitable form for use as a curative or remedial substance taken either internally or externally by any person.

  • Medical cannabis card means the same as that term is defined in Section 26-61a-102.